Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma
Belantamab mafodotin-blmf (Blenrep) plus carfilzomib, lenalidomide (Revlimid), and dexamethasone (KRd) was associated with a manageable safety profile, including manageable keratopathy, and early evidence of deep responses in patients with multiple myeloma …